Login / Signup

Efficacy of Xanthine Oxidase Inhibitors in Lowering Serum Uric Acid in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Yoojin LeeJennifer HwangShaan H DesaiXiaobai LiChristopher JenkinsJeffrey B KoppCheryl A WinklerSung Kweon Cho
Published in: Journal of clinical medicine (2022)
Allopurinol, febuxostat, and topiroxostat showed dose-proportional ability to lower and achieve a target SUA < 6 mg/dL. Significance and Innovations. We showed dose-dependent SUA lowering effects of allopurinol, febuxostat, and topiroxostat. Febuxostat is effective at ULT compared to allopurinol and could be potentially offered as an alternative agent when patients (1) have CKD, (2) have the human leukocyte antigen HLA-B*5801 allele, and (3) become refractory to allopurinol. Gradual allopurinol dose increase with a lower starting dose is needed in CKD.
Keyphrases
  • uric acid
  • chronic kidney disease
  • end stage renal disease
  • metabolic syndrome
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • patient reported outcomes